Description
Contents
Perindopril/Indapamide
Indications/Uses
Coversyl Plus 10 mg/2.5 mg is indicated as substitution therapy for treatment of essential hypertension, in patients already controlled with perindopril and indapamide given concurrently at the same dose level.
Dosage/Direction for Use
Posology: One Coversyl Plus 10mg/2.5mg tablet per day as a single dose, preferably to be taken in the morning, and before a meal.
Special populations:Β Elderly (see Precautions):Β In elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated if renal function is normal and after considering blood pressure response.
Renal impairment (see Precautions):Β In severe and moderate renal impairment (creatinine clearance below 60 ml/min), treatment is contraindicated.
Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see Contraindications, Precautions and Pharmacology: Pharmacokinetics under Actions):Β In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Paediatric population:Β The safety and efficacy of Coversyl Plus 10mg/2.5mg in children and adolescents have not yet been established. No data are available. Coversyl Plus 10mg/2.5mg should not be used in children and adolescents.
Special populations:Β Elderly (see Precautions):Β In elderly, the plasma creatinine must be adjusted in relation to age, weight and gender. Elderly patients can be treated if renal function is normal and after considering blood pressure response.
Renal impairment (see Precautions):Β In severe and moderate renal impairment (creatinine clearance below 60 ml/min), treatment is contraindicated.
Usual medical follow-up will include frequent monitoring of creatinine and potassium.
Hepatic impairment (see Contraindications, Precautions and Pharmacology: Pharmacokinetics under Actions):Β In severe hepatic impairment, treatment is contraindicated.
In patients with moderate hepatic impairment, no dose modification is required.
Paediatric population:Β The safety and efficacy of Coversyl Plus 10mg/2.5mg in children and adolescents have not yet been established. No data are available. Coversyl Plus 10mg/2.5mg should not be used in children and adolescents.
*The product images shown are for illustration purposes only and may not be an exact representation of the product.
